MW390A1 - Antiviral or antibacterial compound and method of use - Google Patents

Antiviral or antibacterial compound and method of use

Info

Publication number
MW390A1
MW390A1 MW3/90A MW390A MW390A1 MW 390 A1 MW390 A1 MW 390A1 MW 3/90 A MW3/90 A MW 3/90A MW 390 A MW390 A MW 390A MW 390 A1 MW390 A1 MW 390A1
Authority
MW
MALAWI
Prior art keywords
antiviral
composition
disclosed
antibacterial compound
forms
Prior art date
Application number
MW3/90A
Other languages
English (en)
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of MW390A1 publication Critical patent/MW390A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MW3/90A 1988-05-26 1990-01-22 Antiviral or antibacterial compound and method of use MW390A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17858888A 1988-05-26 1988-05-26
PCT/US1988/001785 WO1989011294A1 (fr) 1988-05-26 1988-05-26 Compose antiviral ou antibacterien et procede d'utilisation
OA59731A OA09785A (en) 1988-05-26 1990-01-26 Antiviral or antibacterial compound and method of use

Publications (1)

Publication Number Publication Date
MW390A1 true MW390A1 (en) 1990-11-14

Family

ID=33162813

Family Applications (1)

Application Number Title Priority Date Filing Date
MW3/90A MW390A1 (en) 1988-05-26 1990-01-22 Antiviral or antibacterial compound and method of use

Country Status (23)

Country Link
US (3) US5200182A (fr)
EP (1) EP0380484B1 (fr)
JP (1) JPH0649659B2 (fr)
AT (1) ATE93143T1 (fr)
AU (1) AU624331B2 (fr)
BG (1) BG60544B1 (fr)
CA (1) CA1335425C (fr)
CS (1) CS277030B6 (fr)
DK (1) DK173078B1 (fr)
ES (1) ES2011577A6 (fr)
FI (1) FI900412A0 (fr)
HK (1) HK42394A (fr)
HU (1) HU204710B (fr)
IL (1) IL90092A (fr)
LV (1) LV10054B (fr)
MA (1) MA21560A1 (fr)
MW (1) MW390A1 (fr)
OA (1) OA09785A (fr)
PH (1) PH26284A (fr)
RU (1) RU2092183C1 (fr)
WO (1) WO1989011294A1 (fr)
YU (1) YU109289A (fr)
ZA (1) ZA893382B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0380484B1 (fr) * 1988-05-26 1993-08-18 Nika Health Products Limited Utilisation d'un dimère de lysozyme et/ou d'un dimère de ribonuclease par la fabrication d'un médicament antiviral ou antibiotique
ES2086403T3 (es) * 1990-01-08 1996-07-01 Nika Health Products Ltd Procedimiento para la elaboracion de dimeros de ribonucleasa.
US5989880A (en) * 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
CH682541A5 (de) * 1992-06-23 1993-10-15 Urs Viktor Dr Wirth Biochemische Inaktivierung von RNA-Viren.
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
JP2002187853A (ja) * 2000-12-21 2002-07-05 Shinei Ferumentekku:Kk 動物の乳頭除菌剤および菌環境改善方法
DE10210285A1 (de) * 2002-03-08 2003-11-13 Medigene Ag Reversibles Toxin und seine Verwendung
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US7348301B2 (en) * 2006-02-16 2008-03-25 Buckman Laboratories International, Inc. Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
WO2007149594A2 (fr) * 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Ribonucléases modifiées
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
WO2008109401A2 (fr) * 2007-03-02 2008-09-12 Saint Simeon Lda Composition et procédé de traitement du virus de papillome et des sarcoïdes équins
US20100317677A1 (en) * 2007-09-11 2010-12-16 Hassel Bret A Methods of Treating a Microbial Infection by Modulating RNase-L Expression and/or Activity
WO2009048909A1 (fr) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions et procédés pour des thérapies à base de ribonucléase
JP2012504423A (ja) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド 治療用リボヌクレアーゼ
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
PL2457576T3 (pl) 2010-11-29 2021-04-06 Eurochit Danuta Kruszewska Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji
RU2548803C2 (ru) * 2011-11-28 2015-04-20 Общество с ограниченной ответственностью " Фарматренд" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ ИНФЕКЦИЙ P. Aeruginosa, СОДЕРЖАЩАЯ РЕКОМБИНАНТНЫЙ ЛИЗОЦИМ
RU2509801C2 (ru) * 2012-03-22 2014-03-20 Борис Михайлович Куриненко СПОСОБ ИСПОЛЬЗОВАНИЯ РИБОНУКЛЕАЗЫ Bacillus intermedius
EP2674162A1 (fr) 2012-05-29 2013-12-18 Danuta Kruszewska Nano-produit, comprenant des lactobacillus reuteri dan080, utile dans la prophylaxie, diagnostic et traitement médical et vétérinaire
EA201491272A1 (ru) 2012-05-29 2015-10-30 Данута Кружевска Нанопродукт, содержащий lactobacillus reuteri dan080, подходящий для профилактики и терапии - человеческой и ветеринарной, и его медицинское применение
RU2504397C1 (ru) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
US9950075B2 (en) 2013-03-15 2018-04-24 The University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
KR102437992B1 (ko) 2014-02-21 2022-08-29 고쿠리츠 다이가쿠 호우징 도쿄 가이요우 다이가쿠 노로 바이러스 불활화제 및 그 제조 방법, 노로 바이러스 불활화 방법, 노로 바이러스 불활화용 라이소자임류의 제조 방법, 노로 바이러스 감염의 예방약 또는 치료약, 그리고 노로 바이러스 불활화용 피부 외용제
KR20170038829A (ko) * 2014-07-31 2017-04-07 큐피가부시키가이샤 함수 유동상 조성물 및 그 제조 방법, 그리고 리소자임 가공품 및/또는 그 염 그리고 그 제조 방법
BR122023020863A2 (pt) 2014-09-17 2024-01-30 Spogen Biotech Inc Método para estimular o crescimento de plantas
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
RU2634264C1 (ru) * 2016-09-19 2017-10-24 Александр Ливиевич Ураков Крем-молочко для лечения опоясывающего лишая
CN113861760B (zh) 2016-12-28 2023-05-05 Dic株式会社 分散体
US20220273733A1 (en) * 2019-07-26 2022-09-01 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1268M (fr) * 1961-06-29 1962-04-24 Puiseux Médicament antimitotique et antiviral.
FR4020M (fr) * 1965-01-29 1966-03-21
DE1517751C3 (de) * 1965-07-08 1975-02-27 Eisai Co., Ltd., Tokio Verfahren zum Verhindern der Bildung von flockigen Lysozym- und/oder Lysozymsalzniederschlägen in wässrigen Lösungen, die Lysozym und/oder Lysozymsalze enthalten
DE1545644A1 (de) * 1965-12-06 1969-08-07 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen quaternaeren Scopolammoniumsalzen
GB1110504A (en) * 1966-03-18 1968-04-18 Prodotti Antibiotici Spa Pharmaceutical compositions
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
CA1263378A (fr) * 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinoleines, utiles comme agents immunomodulateurs
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
EP0380484B1 (fr) * 1988-05-26 1993-08-18 Nika Health Products Limited Utilisation d'un dimère de lysozyme et/ou d'un dimère de ribonuclease par la fabrication d'un médicament antiviral ou antibiotique

Also Published As

Publication number Publication date
DK16890D0 (da) 1990-01-22
ATE93143T1 (de) 1993-09-15
FI900412A0 (fi) 1990-01-25
YU109289A (en) 1991-08-31
DK173078B1 (da) 1999-12-20
JPH03504121A (ja) 1991-09-12
ZA893382B (en) 1991-01-30
AU1940888A (en) 1989-12-12
EP0380484B1 (fr) 1993-08-18
IL90092A (en) 1995-03-30
HUT54060A (en) 1991-01-28
LV10054A (lv) 1994-05-10
US5200182A (en) 1993-04-06
US5466449A (en) 1995-11-14
CA1335425C (fr) 1995-05-02
WO1989011294A1 (fr) 1989-11-30
HK42394A (en) 1994-05-13
HU883981D0 (en) 1990-12-28
EP0380484A1 (fr) 1990-08-08
ES2011577A6 (es) 1990-01-16
PH26284A (en) 1992-04-10
BG60544B1 (en) 1995-08-28
OA09785A (en) 1994-04-15
CS277030B6 (en) 1992-11-18
RU2092183C1 (ru) 1997-10-10
LV10054B (en) 1995-02-20
US6099835A (en) 2000-08-08
AU624331B2 (en) 1992-06-11
CS318089A3 (en) 1992-05-13
JPH0649659B2 (ja) 1994-06-29
HU204710B (en) 1992-02-28
DK16890A (da) 1990-01-22
MA21560A1 (fr) 1989-12-31

Similar Documents

Publication Publication Date Title
ZA893382B (en) Antiviral or antibacterial compound and method of use
CA2068324A1 (fr) Compositions peptidiques renfermant un metal et methodes de stimulation de la croissance des cheveux
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MX9702932A (es) L-ribofuranosilnucleosidos.
AU7211787A (en) Intraocular dosage compositions and method of use
MY110734A (en) Improvements in or relating to dioic acids.
IL84510A (en) Agents for combating pests and plant treatment agents consisting of microorganism granulates
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ZA929947B (en) Method of imparting antimicrobial activity to an opthalmic composition.
JO1610B1 (en) Tetrahydimidimidose compounds (1,4) benzodiazepine-2 thyonath anti-viral and anti-viral
MX9706689A (es) Tratamiento de trastornos causados por el factor de crecimiento de citocina.
AU2840889A (en) Method of treating haematologic diseases and pharmaceutical compositions to be used therefor
JO1589B1 (en) Ketones (quaternary hydroimidazo (4.1) benzo-diazepine-2) anti-viral
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
MY106984A (en) Antiviral or antibacterial composition and method of use.
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof
AU6600190A (en) Therapeutic compositions; methods for treatment of hiv infections
GR1001006B (el) Μεθοδος παρασκευης και χρησιμοποιησεως αντιιικων η αντιβακτηριακων συνθεσεων.
AU3575189A (en) Long lasting composition of propafenone and quinidine for treatment of cardiac conditions
AU2314488A (en) Anthelmintic acylhydrazones, method of use and compositions
MX9307639A (es) Metodo para tratar infecciones virales con terapia conjuntiva con compuestos similares al aciclovir y un analogo de nucleosido 2'-viril substituido.
MY104932A (en) Immunomodulatory azaspiranes
HRP930588B1 (en) Process for the preparation of therapeutic transdermal system having physostigmine as an active ingredient